<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560647</url>
  </required_header>
  <id_info>
    <org_study_id>06956</org_study_id>
    <nct_id>NCT04560647</nct_id>
  </id_info>
  <brief_title>Pilot Studies Testing Levels of P63 in Psoriasis Skin Lesions</brief_title>
  <official_title>Pilot Studies Testing Levels of P63 in Psoriasis Skin Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wright State Physicians</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wright State Physicians</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the role of a specific protein, tumor protein p63&#xD;
      in the skin disease psoriasis. This study is to further understand how psoriasis lesions&#xD;
      happens. An understanding of key mediators that lead to psoriasis might aid in the discovery&#xD;
      of more effective treatments for this skin disorder. This is not an intervention study. The&#xD;
      study is looking to obtain currently untreated plaque psoriasis biopsies and also biopsies&#xD;
      from non psoriasis patients. Psoriasis and medical history will be collected then skin&#xD;
      biopsies will be obtained from the subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Abnormal P63 signaling levels</measure>
    <time_frame>Day 0</time_frame>
    <description>Determining if untreated psoriasis skin has abnormal p63 signaling</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
    <description>Subjects diagnosed with psoriasis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Subjects who do not have psoriasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention - Psoriasis Subject</intervention_name>
    <description>Not currently treated plaque psoriasis patients</description>
    <arm_group_label>Psoriasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention - Control Subject</intervention_name>
    <description>Control subjects without plaque psoriasis and no family history of psoriasis</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Plaque psoriasis patients and control patients from the Dayton, OH area.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and Male adult subjects age 18 to 50 with plaque psoriasis that is currently&#xD;
             untreated (no topical agents for 2 weeks, no systemic agents for 1 month) or controls&#xD;
             w/o psoriasis and no family history of psoriasis.&#xD;
&#xD;
          -  Must be able to give informed consent&#xD;
&#xD;
          -  All skin types on Fitzpatrick Scale (Type I-VI)&#xD;
&#xD;
          -  Able to provide medical history and list of medications for psoriasis and control&#xD;
             subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes&#xD;
             mellitus)&#xD;
&#xD;
          -  Tanning bed use within last 2 months&#xD;
&#xD;
          -  Photodynamic Therapy or UVB treatments in past 2 months&#xD;
&#xD;
          -  Female Subjects: pregnant or nursing&#xD;
&#xD;
          -  History of abnormal scarring (i.e., keloids)&#xD;
&#xD;
          -  Family history of psoriasis in first-degree relatives for control subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey B Travers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wright State Physicians Pharmacology Translational Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manager Clinical Research Operations</last_name>
    <phone>937-245-7500</phone>
    <email>pturesearch@wrightstatephysicians.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regulatory Specialist</last_name>
    <phone>937-245-7500</phone>
    <email>pturesearch@wrightstatephysicians.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wright State Physicians</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wright State Physicians</investigator_affiliation>
    <investigator_full_name>Jeffrey B. Travers, MD, PhD</investigator_full_name>
    <investigator_title>Chair of Department of Pharmacology and Toxicology and Professor of Dermatology for Boonshoft School of Medicine at Wright State University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

